Imaging Inflammation in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Alzheimer's Disease
Interventions
DRUG

11C-PBR28

11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.

DRUG

18F-Florbetaben

18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.

PROCEDURE

Lumbar puncture (optional)

Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.

Trial Locations (1)

10032

Columbia University irving Medical Center, New York

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Patrick Lao

OTHER

NCT02831283 - Imaging Inflammation in Alzheimer's Disease | Biotech Hunter | Biotech Hunter